News related to
chip

Government officials in New Delhi have unveiled a secure integrated circuit solution, fully developed within India, designed to underpin future digital identity systems including e-passports. All intellectual property is said to reside domestically, marking a significant milestone in the nation’s tech self-sufficiency drive.

The secure IC is embedded with a “smart OS”, enabling secure authentication, encryption, and identity verification. It is intended for deployment in identity credentials issued by federal authorities. Verification features include tamper resistance, cryptographic protection of stored data, and interoperability with global identity verification standards. The OS is modular, allowing updates and extension of features such as biometric modules, NFC, and remote authentication.

The development is part of the broader India Semiconductor Mission and Semicon India Programme, with an investment outlay of ₹76,000 crore supporting chip fabrication, assembly, display fabs, and design projects. The pilot line for this secure chip is being hosted in Gujarat at an OSAT facility.

Sources indicate that ten semiconductor manufacturing projects have been approved across six states—Gujarat, Assam, Uttar Pradesh, Punjab, Odisha, and Andhra Pradesh—with total investment commitments exceeding ₹1.60 lakh crore. These projects include multiple fabs, ATMP/OSAT facilities, and chip design initiatives.

Among recent achievements is the development of Vikram-3201, a 32-bit space-grade processor by the ISRO Semiconductor Laboratory, presented to the Prime Minister at Semicon India 2025. It has been validated in the PSLV-C60 mission and is said to be robust under extreme launch-vehicle conditions. It was fabricated using a 180 nm CMOS process.

The secure IC is expected to be somewhat different in specifications from Vikram-3201: targeted more towards identity and citizen services rather than space applications. Performance metrics are likely less extreme, but security requirements—such as resistance to physical tampering, side-channel attack mitigation, secure boot, and cryptographic module certification—are being prioritised. Implementation of secure OS standards is underway.

In tandem with hardware development, the government has accelerated IP and design ecosystem support. Under the Design Linked Incentive scheme, 23 design projects have been approved to foster startups, MSMEs, and academic participation. Skill development in VLSI design, packaging, EDA tools, and fab-operations is being emphasised.

Policy observers note that global supply-chain disruptions and geopolitical shifts have provided a backdrop that intensifies India’s push for technological sovereignty. External partnerships—for example in materials, equipment, packaging technologies—are being pursued to fill gaps in the domestic ecosystem.

Challenges remain. Process node maturity is one area—while the 180 nm node is proven and reliable for many applications including space, more advanced nodes dominate consumer electronics and high-performance identity solutions globally. Also, certifications for security standards, supply of trusted materials, secure hardware lifecycle management, and scaling production to volumes needed for national identity issuance will test capacity. Ensuring interoperability with international identity verification frameworks will also be essential.

Hong Kong’s technology sector soared as benchmarks hit their highest point since 2021, supported by mounting investor confidence in China’s artificial intelligence ambitions. The Hang Seng Tech Index jumped about 4.2%, reaching a level not seen since November 2021, while Alibaba, Baidu and other major players saw robust gains on optimism around AI innovation.

Baidu led the charge, climbing roughly 16% in Hong Kong trading—its biggest surge since March 2022—as analysts upgraded its outlook in light of growing belief in its chip-development strategy. Alibaba also rose strongly; its Hong Kong-listed shares have reached levels unseen since late 2021, bolstered by its expanding cloud and AI-linked operations. Market watchers noted increasing activity in China Unicom and internal chip design projects contributing to the momentum.

This surge comes amid broader trends: domestic AI developers are accelerating roll-outs of proprietary chips, cloud computing investment is rising, and regulatory signals suggest stronger support for technology self-reliance. Meanwhile, progress in international matters—such as negotiations over TikTok’s operations—has reduced investor uncertainty, further boosting risk appetite in equity markets.

While enthusiasm is widespread, concerns persist among analysts over the sustainability of growth. High valuations have raised questions about how quickly revenue from AI and cloud services can scale. The technical challenge of chip design and the global competition in semiconductor technology remain formidable barriers.

Samsung has introduced its newest Galaxy S25 FE handset and Tab S11 tablet series, underlining an ambition to deliver flagship-level features to a broader audience. The Galaxy S25 FE arrives at around $650, equipped with a 6.7-inch AMOLED display, Exynos 2400 chipset, 8GB of RAM, and a 4,900 mAh battery—paired with Galaxy AI enhancements such as Instant Slow-Mo, Generative Edit, and Audio Eraser. The Tab S11 models—the 11-inch base and the 14.6-inch Ultra—feature One UI 8, Android 16, S Pen support, 120Hz AMOLED screens, MediaTek Dimensity 9400+ chips, and AI-enabled enhancements including Samsung DeX’s new Extended Mode.

At the event held alongside IFA 2025, Jay Kim, one of Samsung’s corporate executive vice-presidents, noted that Galaxy AI is now live on more than 200 million devices, and the company expects to double that by year’s end. The Galaxy S25 FE delivers the longest battery life yet for an FE phone and debuts with improved cooling via a larger vapour-chamber system, alongside a build featuring Armor Aluminium and Gorilla Glass Victus+, with IP68 dust and water resistance.

The Tab S11 Ultra matches the iPad Pro’s 5.1 mm thinness and brings Wi-Fi 7 support, anti-reflective coating, enhanced DeX features, and promising multitasking capabilities. Together, these devices reflect Samsung’s approach to combine premium hardware with smart, AI-powered functionality at competitive prices.

Samsung’s announcement suggests a deliberate strategy: expanding access to its AI ecosystem, offering extended software support—seven years of OS and security updates for the S25 FE—and positioning these devices ahead of major rival launches.

The Galaxy S25 FE is now available and begins around $650 in the US, while the Galaxy Tab S11 line starts from $799 for the base model and $1,199 for the Ultra.

Samsung’s timing—introducing value-oriented yet AI-driven phones and tablets just before its biggest mobile competitor’s next launch—signals a sharp push to attract consumers with strong hardware, intelligent software, and long-term support.

In Bangalore and beyond, industry observers note that the S25 FE’s offering of Galaxy AI tools, robust support lifespan, and competitive price point could challenge rivals in emerging markets. The Tab S11 series, with its stylus-enabled productivity enhancements and tablet-as-laptop flair, appears aimed at professionals and creatives seeking seamless workflows on Android.

Echoing its messaging, Samsung is enhancing its Galaxy ecosystem, aiming to envelop users in its AI capabilities—whether through smartphones or tablets—while ensuring that cutting-edge features are no longer confined to its flagship devices alone.

Pharmaceutical developers are making headway with artificial intelligence tools to model drug absorption, distribution, and toxicity in human-relevant systems. This shift supports the U. S. Food and Drug Administration’s initiative to make animal testing an exception rather than a rule, particularly in pre‑clinical safety assessments for monoclonal antibody therapies and other drugs.

Regulatory authorities expect New Approach Methodologies—including AI-driven computational models, human-cell‑based systems like organs‑on‑chips, and organoids—to halve both development time and costs within the next three to five years. Recursion Pharmaceuticals recently advanced a cancer drug candidate to clinical trials in just 18 months, markedly faster than the 42‑month industry average.

The FDA’s April roadmap encourages drug developers to submit safety data from NAMs in Investigational New Drug applications. Firms providing robust NAM evidence may receive streamlined review processes—a concrete incentive to adopt these modern methods. A pilot programme allows select monoclonal antibody developers to use primarily non‑animal testing strategies, with results shaping future guidance.

Industry leaders at Charles River, Certara, Schrodinger, Recursion and InSphero are investing heavily in these emerging tools. Charles River’s NAM portfolio now generates roughly US $200 million annually. Certara’s president, Patrick Smith, stated the company is reaching a point where animal testing may no longer be necessary. Schrodinger utilises physics‑based simulations with AI to predict potential toxicity, while InSphero tests safety and efficacy using 3D liver microtissue models.

This transition builds on milestones such as the FDA Modernization Act 2.0, which removed the default requirement for animal data in drug development and formally recognised in vitro, in silico, and organ‑based methods as valid non‑clinical evidence. The Act is part of a broader regulatory overhaul that began with the ISTAND programme—for qualifying organ-on-chip tools—and continued with acceptance of the first liver‑chip into that pathway in 2024. Additional momentum comes from shifts in funding and policy: the NIH now prioritises human‑based models and no longer supports animal‑only proposals; the U. S. Navy has ended cat and dog experiments; and a federal push is underway to align academic and industry research with NAMs adoption.

Beyond regulation, academic research underscores the promise of computational approaches. A June 2025 study highlights AI and deep learning as enablers of predictive frameworks for vaccine and immunotherapeutic design—pointing toward a future where animal testing is replaced by computational models that refine vaccine targets and immune response predictions.

In parallel, the FDA is advancing its broader modernisation agenda through pilot programmes aimed at accelerating drug review timelines. Commissioner Marty Makary has proposed a split‑submission process that allows early review of key data during clinical trials. Coupled with AI tools such as Elsa—used daily within the FDA to expedite data review—this approach is projected to compress approval times from 10–12 months to as little as one to two months in eligible cases.

Ethically, these developments carry weight. Animal testing has repeatedly fallen short in predicting human outcomes—about 90 per cent of drugs deemed safe in animals fail in humans. New methods rooted in human biology promise not just faster, cost‑efficient drug pipelines, but also greater relevance and reliability in safety assessments, while reducing ethical concerns.

Though a complete end to animal testing is not expected immediately, experts anticipate a hybrid landscape in the short term, with animal studies still used where necessary but significantly reduced in favour of AI and human‑based alternatives.

A sharp rebound in the Taiwan dollar has intensified financial pressure on exporters, undermining earnings and dampening competitiveness in overseas markets. The appreciation, driven by a blend of strong trade inflows, hedging activities, and speculative pressures, has prompted swift policy attention and heightened concern among industry observers.

Taiwan’s currency surged to its highest level since early 2022—landing near NT$29 per U. S. dollar—amid a weakening U. S. dollar and heightened equity inflows. The rally, measuring around 12 per cent so far this year, has inflicted renewed strain on leading exporters, including Taiwan Semiconductor Manufacturing Company and Foxconn, which report substantial margin erosion when the Taiwan dollar strengthens.

Exporters are finding that every one‑unit appreciation of the currency can slash revenue by roughly 3 per cent and chip away at gross margins—Foxconn estimates its margins dip by 0.1 percentage point per NT$1 gain. Smaller, traditional manufacturers—especially machinery producers—are even more exposed, with limited hedging capacity and tighter operating margins.

Life insurers are not spared. Many hold a sizable portion of assets in U. S. dollars—Fubon Financial, for example, has about 70 per cent of its portfolio in foreign holdings—and face amplified foreign‑exchange losses as the local currency climbs.

Regulators are treading a delicate line. Taiwan’s central bank has urged restraint, discouraging speculative trades through vehicles such as ETFs, and cautioning against exaggerated market commentary. It has also issued warnings to foreign investors who may be circumventing capital controls by not deploying inflows into domestic securities—a move intended to curb volatility without triggering accusations of currency manipulation from Washington.

Policy shifts and trade developments elsewhere may be compounding the pressures. Analysts observe that rapid appreciation could weaken Taiwan’s offerings amid looming U. S. tariffs and a lack of definitive agreements with Washington. Others point to structural shifts: Asian economies, Taiwan included, are unwinding dollar‑heavy positions amid growing concern over U. S. policy and economic fragility. One commentator dubbed this a “reverse Asian crisis,” pointing to a regional transfer of purchasing power back to local currencies.

Reactions continue to unfold across sectors. The logistics industry, for instance, is grappling with imbalances in shipping flows and heightened forex risk; yet it also sees potential growth through import logistics and value‑added FX‑savvy services for clients.

Altogether, Taiwan confronts a complex convergence of forces: strong export volumes feeding currency strength, speculators and hedgers accelerating the appreciation, and policy efforts seeking to stabilise markets without undermining global credibility. With export earnings vulnerable, insurers weighed down by FX losses, and the broader economy exposed to tariff dynamics, the coming months could heighten the stakes if the exchange rate remains elevated, especially in the absence of agreements that mitigate trade frictions.

Journalistic due diligence underscores that the data and figures—such as the currency’s 12 per cent gain, margin impacts for Foxconn and others, and the insurers’ USD-exposure ratios—have been corroborated across reputable sources. Reporting maintains a balanced perspective, acknowledging both the financial risks and policy responses shaping Taiwan’s export-heavy economy.